Ranbaxy Laboratories’ wholly owned subsidiary - Ranbaxy Pharmaceuticals Inc. has launched an authorized generic version of Caduet in the US market, as part of an agreement with Pfizer Inc. The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol.
Caduet is a fixed-dose combination of Atorvastatin-Amlodipine besylate, presently marketed by Pfizer under the brand Caduet, which also contains a crystalline form of Atorvastatin. Caduet generated total annual sales of $339 million in the US, as per IMS - MAT September 2011. The company is making available the full range of the generic version of Caduet.
Recently, Ranbaxy Laboratories had received US health regulator’s approval to produce generic version of cholesterol lowering drug Lipitor, a move that will help the India-based firm to launch the drug in the American market.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: